iCAD and Koios Medical Unite to Launch Comprehensive AI-Powered Breast Cancer Detection Platform
核心洞察
iCAD and Koios Medical (搜索) announce strategic partnership to integrate ProFound AI (搜索) Breast Health Suite with Koios SmartUltrasound (搜索), creating a comprehensive AI-powered breast cancer (搜索) detection solution.
The collaboration addresses the growing need for advanced diagnostic tools, particularly benefiting women with dense breast tissue who require alternatives to traditional mammography.
The integrated platform aims to enhance workflow efficiency and diagnostic accuracy by providing radiologists with AI-powered capabilities across both mammography and ultrasound modalities.
In a significant development for breast cancer (搜索) diagnostics, iCAD, Inc. (NASDAQ: ICAD) and Koios Medical (搜索) have announced a strategic partnership to deliver an integrated artificial intelligence platform combining mammography and ultrasound detection capabilities. The collaboration merges iCAD's ProFound AI (搜索)® Breast Health Suite with Koios SmartUltrasound (搜索)™, creating a comprehensive solution for breast cancer screening and diagnosis.
Enhanced Detection Through Multi-Modal AI Integration
The partnership addresses a critical need in breast cancer (搜索) diagnostics by providing radiologists with an AI-powered pathway from initial screening to final diagnosis. This integration is particularly valuable for the more than 40% of women in the US who have dense breast tissue and often require ultrasound imaging as an alternative to traditional mammography.
"By offering an integrated 'breast AI suite' that includes both iCAD's ProFound AI (搜索) and Koios SmartUltrasound (搜索), we're enabling a more comprehensive, AI-enhanced patient pathway," explained Chad McClennan, President & CEO of Koios Medical (搜索). The combined solution aims to streamline AI implementation across both mammography and breast ultrasound modalities.
Clinical Impact and Technological Advantages
The Koios SmartUltrasound (搜索) platform has demonstrated effectiveness in detecting and diagnosing both thyroid and breast cancers in ultrasound examinations. The system leverages data from a global network of healthcare facilities to:
- Improve interpretation speed
- Automate reporting processes
- Reduce time to treatment
- Minimize unnecessary surgical procedures
Dana Brown, President and CEO of iCAD, emphasized the partnership's strategic importance: "This collaboration reinforces iCAD's commitment to delivering innovative AI solutions that empower radiologists and improve patient outcomes. The integrated approach enhances both workflow efficiency and diagnostic accuracy."
Implementation and Availability
The combined solution will be showcased at ECR 2025 in Vienna, Austria, where healthcare professionals can experience firsthand the integration of these advanced AI technologies. The platform represents a significant step forward in the evolution of breast cancer (搜索) diagnostics, offering healthcare providers a more comprehensive tool for early detection and accurate diagnosis.
This strategic partnership reflects the growing adoption of AI solutions in breast imaging facilities and responds to increasing demand from healthcare providers for more efficient and accurate diagnostic tools. The integration particularly benefits facilities serving patients who require multiple imaging modalities for comprehensive breast cancer (搜索) screening and diagnosis.